Mohammed Abu Mahfouz, MD
Internal Medicine · Detroit, MINPI 1992873418
Payments from drug & device makers
Across 388 payments — averaging $29.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Alnylam Pharmaceuticals Inc.$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Novartis$891
- Boston Scientific$863
- Johnson & Johnson$765
- plus $4K from 35 others
What the payments were for
- Consulting fees$1,86016%
- Food & beverage$9,68384%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 30 | $2,473 |
| Alnylam Pharmaceuticals Inc. | 46 | $1,262 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $1,132 |
| Novartis | 46 | $891 |
| Boston Scientific | 21 | $863 |
| Johnson & Johnson | 42 | $765 |
| Boehringer Ingelheim | 33 | $677 |
| Merck | 23 | $458 |
| Pfizer | 20 | $362 |
| Kestra Medical Technology Services, Inc. | 7 | $282 |
| Cardiovascular Systems Inc. | 3 | $234 |
| Amgen | 8 | $206 |
| Abiomed | 3 | $204 |
| E.r. Squibb & Sons, L.L.C. | 11 | $189 |
| Tactile Systems Technology Inc | 4 | $182 |
| GSK | 2 | $149 |
| Abbott | 8 | $145 |
| Actelion Pharmaceuticals US, Inc. | 4 | $144 |
| Novo Nordisk | 8 | $137 |
| Lexicon Pharmaceuticals, Inc. | 6 | $98 |
| Bridgebio Pharma, Inc. | 3 | $90 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Bayer | 3 | $53 |
| Stryker | 2 | $51 |
| Shockwave Medical, Inc | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $48 |
| Heartflow, Inc. | 2 | $41 |
| Chiesi USA, Inc. | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $34 |
| Preventice Services, LLC | 2 | $34 |
| Baxter Healthcare | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Cordis US CORP. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| ZOLL Circulation Inc | 1 | $19 |
| Teleflex LLC | 1 | $16 |
| Sobi, Inc | 1 | $16 |
| Elutia, Inc. | 1 | $13 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$468
- Varithena Administration Pack$148
- WATCHMAN Access System$144
- Flexitouch Plus$133
- ENTRE$133
- WAINUA$125
- ENTRESTO$125
- Peripheral Orbital Atherectomy System$112
- XARELTO$111
- Assure WCD$110
- LATITUDE$102
- JARDIANCE$101
How this compares
$11,566 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 197 | $168,249 |
| EntrestoSacubitril/Valsartan | 119 | $112,021 |
| FarxigaDapagliflozin Propanediol | 126 | $88,971 |
| JardianceEmpagliflozin | 79 | $61,062 |
| XareltoRivaroxaban | 62 | $50,840 |
| BrilintaTicagrelor | 58 | $33,831 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $9,692 |
| Eplerenone | 77 | $5,291 |
| Metoprolol Succinate | 366 | $4,834 |
| Atorvastatin Calcium | 444 | $4,295 |
| Clonidine | 18 | $2,245 |
| Carvedilol | 232 | $2,134 |
| ClopidogrelClopidogrel Bisulfate | 146 | $1,919 |
| Amlodipine Besylate | 344 | $1,802 |
| Losartan Potassium | 171 | $1,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $362 | $168,249197 claims |
| AstraZenecaFarxiga, Brilinta | $2,473 | $122,802184 claims |
| NovartisEntresto | $891 | $112,021119 claims |
| Boehringer IngelheimJardiance | $677 | $61,06279 claims |
| Johnson & JohnsonXarelto | $765 | $50,84062 claims |
| GSKTrelegy Ellipta | $149 | $9,69217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Detroit
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Rana BalboulDetroit$2.4M
- Philip KuriakoseDetroit$1.9M
- Erlene SeymourDetroit$797K
- Sheela TejwaniDetroit$712K
- Vrushali DabakDetroit$509K
- James McCordDetroit$493K
- Saroj NeupaneDetroit$487K
- David StocktonDetroit$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.